Afficher la notice abrégée

T1 Mapping From MPRAGE Acquisitions: Application to the Measurement of the Concentration of Nanoparticles in Tumors for Theranostic Use

hal.structure.identifierInstitut des Sciences Moléculaires [ISM]
dc.contributor.authorLAVIELLE, Audrey
hal.structure.identifierNH TherAguix SA [Meylan]
dc.contributor.authorBOUX, Fabien
hal.structure.identifierInstitut des Sciences Moléculaires [ISM]
dc.contributor.authorDEBORNE, Justine
hal.structure.identifierInstitut des Sciences Moléculaires [ISM]
dc.contributor.authorPINAUD, Noël
hal.structure.identifierNH TherAguix SA [Meylan]
dc.contributor.authorDUFORT, Sandrine
hal.structure.identifierCentre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
dc.contributor.authorVERRY, Camille
hal.structure.identifierCentre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
dc.contributor.authorGRAND, Sylvie
hal.structure.identifierIRMaGe [IRMaGe]
hal.structure.identifierCentre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
dc.contributor.authorTROPRÈS, Irène
hal.structure.identifierInstitut de Chimie de la Matière Condensée de Bordeaux [ICMCB]
dc.contributor.authorVECCO‐GARDA, Clément
hal.structure.identifierNH TherAguix SA [Meylan]
dc.contributor.authorLE DUC, Géraldine
hal.structure.identifierInstitut de Chimie de la Matière Condensée de Bordeaux [ICMCB]
dc.contributor.authorMORNET, Stéphane
hal.structure.identifierInstitut des Sciences Moléculaires [ISM]
dc.contributor.authorCRÉMILLIEUX, Yannick
dc.date.issued2023
dc.identifier.issn1053-1807
dc.description.abstractEnBackground: The measurement of the concentration of theranostic agents in vivo is essential for the assessment of their therapeutic efficacy and their safety regarding healthy tissue. To this end, there is a need for quantitative T 1 measurements that can be obtained as part of a standard clinical imaging protocol applied to tumor patients. Purpose: To generate T 1 maps from MR images obtained with the magnetization-prepared rapid gradient echo (MPRAGE) sequence. To evaluate the feasibility of the proposed approach on phantoms, animal and patients with brain metastases. Study Type: Pilot. Phantom/Animal model/Population: Solutions containing contrast agents (chelated Gd 3+ and iron nanoparticles), male rat of Wistar strain, three patients with brain metastases. Field Strength/Sequence: A 3-T and 7-T, saturation recovery (SR), and MPRAGE sequences. Assessment: The MPRAGE T 1 measurement was compared to the reference SR method on phantoms and rat brain at 7-T. The robustness of the in vivo method was evaluated by studying the impact of misestimates of tissue proton density. Concentrations of Gd-based theranostic agents were measured at 3-T in gray matter and metastases in patients recruited in NanoRad clinical trial. Statistical Tests: A linear model was used to characterize the relation between T 1 measurements from the MPRAGE and the SR acquisitions obtained in vitro at 7-T. Results: The slope of the linear model was 0.966 (R 2 = 0.9934). MPRAGE-based T 1 values measured in the rat brain were 1723 msec in the thalamus. MPRAGE-based T 1 values measured in patients in white matter and gray matter amounted to 747 msec and 1690 msec. Mean concentration values of Gd 3+ in metastases were 61.47 μmol. Data Conclusion: The T 1 values obtained in vitro and in vivo support the validity of the proposed approach. The concentrations of Gd-based theranostic agents may be assessed in patients with metastases within a standard clinical imaging protocol using the MPRAGE sequence. Evidence Level: 2. Technical Efficacy: Stage 1.
dc.description.sponsorshipInitiative d'excellence de l'Université de Bordeaux - ANR-10-IDEX-0003
dc.description.sponsorshipTranslational Research and Advanced Imaging Laboratory - ANR-10-LABX-0057
dc.language.isoen
dc.publisherWiley-Blackwell
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/
dc.subject.enGd-based nanoparticle
dc.subject.enMPRAGE
dc.subject.enT1 map
dc.subject.entheranostic agent
dc.subject.entumor
dc.title.enT1 Mapping From MPRAGE Acquisitions: Application to the Measurement of the Concentration of Nanoparticles in Tumors for Theranostic Use
dc.typeArticle de revue
dc.identifier.doi10.1002/jmri.28509
dc.subject.halSciences du Vivant [q-bio]/Ingénierie biomédicale/Imagerie
bordeaux.journalJournal of Magnetic Resonance Imaging
bordeaux.page313-323
bordeaux.volume58
bordeaux.issue1
bordeaux.peerReviewedoui
hal.identifierhal-03840727
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-03840727v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Magnetic%20Resonance%20Imaging&rft.date=2023&rft.volume=58&rft.issue=1&rft.spage=313-323&rft.epage=313-323&rft.eissn=1053-1807&rft.issn=1053-1807&rft.au=LAVIELLE,%20Audrey&BOUX,%20Fabien&DEBORNE,%20Justine&PINAUD,%20No%C3%ABl&DUFORT,%20Sandrine&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée